Merck (MRK) says, for Keytruda, expects moderating growth as it approaches peak revenues for certain approved indications and the German market to be impacted by policy dynamics

• Anticipates underlying operating expenses to increase mid- to high-single digits in 2027.

Guidance language of this kind is the standard way large pharma pre-positions the market for a flagship approaching loss of exclusivity: growth moderation is flagged at the indication level first, with peak-revenue framing used to soften the eventual cliff rather than surprise with it. The mechanism that matters for valuation is the gap between the erosion curve on the incumbent franchise and the ramp of whatever is meant to replace it, and commentary that concedes moderation earlier than consensus models assumed has historically compressed the multiple on the franchise rather than just trimming near-term EPS. The reference to German policy dynamics fits a recurring pattern in which reference pricing, rebate negotiations, and reimbursement reviews in single-payer or semi-regulated markets take points off ex-US realized pricing before volume does anything. The opex guide, mid- to high-single digit growth, sits in tension with franchise deceleration and is the sort of pairing that pushes attention to margin trajectory and pipeline spend productivity rather than the top line. Follow-ons of note are the formal guidance detail, any quantification of the Keytruda curve, and whether management frames biosimilar and next-generation subcutaneous or combination strategies as offset or successor. As prepared commentary rather than a print, the signal is about trajectory, not the quarter.